CD1A and Familial prostate cancer: Treatment of three prostate cancer cell lines (22Rv1, LNCaP and VCaP) with GSK126 results in loss of global H3K27 trimethylation, associated with a dramatic increase in expression of all the genes within the CD1A-IFI16 locus (Figures 4I–J and S7F–G).